Vas Narasimhan, Novartis CEO (Akio Kon/Bloomberg via Getty Images)
January 9, 2024 12:55 PM EST
Deals

No­var­tis CEO plays down Cy­to­ki­net­ics buy­out ru­mors in CN­BC in­ter­view

Max Gelman

Senior Editor

No­var­tis CEO Vas Narasimhan threw cold wa­ter on the ru­mors about his com­pa­ny’s po­ten­tial ac­qui­si­tion of the biotech Cy­to­ki­net­ics.

In an

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

Up­dat­ed: As­traZeneca, Dai­ichi Sankyo re­place lung can­cer fil­ing for En­her­tu suc­ces­sor

Apol­lo makes a deal worth up to $926M; Abeona re­sub­mits gene ther­a­py

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times